Politicizing Science
BioPharmaceutical
Report




- Mar 12, 2019
- 6 min
NY-ESO-1 therapy renewed enthusiasm underscored by new checkpoint inhibitors


- Mar 12, 2019
- 7 min
Democratizing Antibodies


- Mar 12, 2019
- 5 min
FDA Review Policies for PD-1/PD-L1 Inhibitors Spark Expert Debate


- Mar 12, 2019
- 5 min
PCSK9 Inhibitor Competition: Amgen, Scanofi, and Regeneron Show Equally Decent CVOT Outlooks


- Mar 12, 2019
- 4 min
South Korea Trials Drive Further Opportunities for Global Pharma and CROs


- Mar 12, 2019
- 12 min
Changing the Channel


- Mar 12, 2019
- 4 min
Early CAR-T multiple myeloma data promising, though efficacy, safety remain unclear


- Mar 12, 2019
- 5 min
Samsung RA biosimilar EU uptake tied to perceived cost despite physician concerns


- Mar 12, 2019
- 10 min
Controlling Drug Prices


- Mar 12, 2019
- 5 min
AbbVie’s Combination Drug for Hepatitis C has Elicited Mixed Expert Opinions


- Mar 12, 2019
- 4 min
No Differentiation Expected Among PARP Inhibitors


- Mar 12, 2019
- 12 min
RULES OF COMPETITION


- Mar 12, 2019
- 4 min
Seattle Genetics/Takeda’s Adcetris, likely to get label expansion


- Mar 12, 2019
- 6 min
US Rheumatologists’ View on Biosimilars